Linnaeus Bioscience pioneered Bacterial Cytological Profiling (BCP), a rapid, image-based method for determining the mechanism of action of antibacterial compounds. Their proprietary technology enables pharmaceutical companies to quickly classify new antibiotics and identify novel targets, accelerating the development of next-generation antimicrobial therapies.